When Gal-9 was combined with CD8 in hepatocellular carcinoma,60 patients with high expression of both Gal-9 and CD8 tended to have longer survival, which was consistent with our finding in SCLC. This evidence concerns the gene LGALS9 and hepatocellular carcinoma.